SK15502001A3 - Použitie Org 33245 - Google Patents
Použitie Org 33245 Download PDFInfo
- Publication number
- SK15502001A3 SK15502001A3 SK1550-2001A SK15502001A SK15502001A3 SK 15502001 A3 SK15502001 A3 SK 15502001A3 SK 15502001 A SK15502001 A SK 15502001A SK 15502001 A3 SK15502001 A3 SK 15502001A3
- Authority
- SK
- Slovakia
- Prior art keywords
- org
- antiprogestagen
- administration
- cycle
- progestagen
- Prior art date
Links
- 230000001838 anti-progestagenic effect Effects 0.000 title claims description 47
- 238000002648 combination therapy Methods 0.000 title abstract description 3
- 239000000583 progesterone congener Substances 0.000 claims abstract description 38
- WAHQVRCNDCHDIB-QZYSPNBYSA-N [(3s,8r,9s,10r,13s,14s,17r)-17-acetyl-17-acetyloxy-6,10,13-trimethyl-1,2,3,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-yl] 3-cyclopentylpropanoate Chemical compound O([C@@H]1C=C2C(C)=C[C@H]3[C@@H]4CC[C@]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)(OC(=O)C)C(C)=O)C(=O)CCC1CCCC1 WAHQVRCNDCHDIB-QZYSPNBYSA-N 0.000 claims abstract description 24
- 239000003433 contraceptive agent Substances 0.000 claims description 13
- 230000002254 contraceptive effect Effects 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000001788 irregular Effects 0.000 claims description 2
- 206010046788 Uterine haemorrhage Diseases 0.000 claims 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 14
- 238000002360 preparation method Methods 0.000 abstract description 4
- 238000002657 hormone replacement therapy Methods 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 229940011871 estrogen Drugs 0.000 description 5
- 239000000262 estrogen Substances 0.000 description 5
- 229960004400 levonorgestrel Drugs 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 4
- 229960004976 desogestrel Drugs 0.000 description 4
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 102000012404 Orosomucoid Human genes 0.000 description 3
- 108010061952 Orosomucoid Proteins 0.000 description 3
- 230000027758 ovulation cycle Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 2
- GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 description 2
- 229960005352 gestodene Drugs 0.000 description 2
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000002957 persistent organic pollutant Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- YJSTYQGZKJHXLN-OLGWUGKESA-N (8r,9s,10r,13s,14s,17r)-17-ethynyl-17-hydroxy-13-methyl-11-methylidene-2,6,7,8,9,10,12,14-octahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](C)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 YJSTYQGZKJHXLN-OLGWUGKESA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000003388 anti-hormonal effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229960002941 etonogestrel Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000000757 progestagenic effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99201390 | 1999-04-29 | ||
| PCT/EP2000/003747 WO2000066129A2 (en) | 1999-04-29 | 2000-04-25 | Use of antiprogestagens in combined therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK15502001A3 true SK15502001A3 (sk) | 2002-03-05 |
Family
ID=8240174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1550-2001A SK15502001A3 (sk) | 1999-04-29 | 2000-04-25 | Použitie Org 33245 |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1178807B1 (es) |
| JP (1) | JP2002543136A (es) |
| KR (1) | KR20010110807A (es) |
| CN (1) | CN1349405A (es) |
| AT (1) | ATE277618T1 (es) |
| AU (1) | AU771059B2 (es) |
| BR (1) | BR0010070A (es) |
| CA (1) | CA2371635A1 (es) |
| CZ (1) | CZ20013874A3 (es) |
| DE (1) | DE60014358D1 (es) |
| HK (1) | HK1041834A1 (es) |
| HU (1) | HUP0201875A3 (es) |
| IL (1) | IL145940A0 (es) |
| MX (1) | MXPA01010976A (es) |
| NO (1) | NO20015207L (es) |
| NZ (1) | NZ514895A (es) |
| PL (1) | PL351678A1 (es) |
| RU (1) | RU2234321C2 (es) |
| SK (1) | SK15502001A3 (es) |
| TR (1) | TR200103116T2 (es) |
| WO (1) | WO2000066129A2 (es) |
| ZA (1) | ZA200108741B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102009017990B4 (de) | 2009-04-21 | 2022-04-07 | Valeo Systèmes d'Essuyage | Flachwischblatt |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA929315B (en) * | 1991-12-20 | 1993-05-24 | Akzo Nv | 17-spirofuran-3'-ylidene steroids. |
| MX9301121A (es) * | 1992-03-02 | 1993-09-01 | Schering Ag | Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina. |
| AU1918092A (en) * | 1992-05-06 | 1993-11-29 | Medical College Of Hampton Roads, The | Minimizing progestin associated breakthrough bleeding |
| ZA935617B (en) * | 1992-08-14 | 1994-03-07 | Akzo Nv | Antiprogestogen containing contraceptives. |
| AU725670B2 (en) * | 1996-06-25 | 2000-10-19 | Akzo Nobel N.V. | Progestogen-anti-progestogen regimens |
-
2000
- 2000-04-25 AT AT00920742T patent/ATE277618T1/de not_active IP Right Cessation
- 2000-04-25 JP JP2000615013A patent/JP2002543136A/ja not_active Withdrawn
- 2000-04-25 SK SK1550-2001A patent/SK15502001A3/sk unknown
- 2000-04-25 AU AU41204/00A patent/AU771059B2/en not_active Ceased
- 2000-04-25 DE DE60014358T patent/DE60014358D1/de not_active Expired - Lifetime
- 2000-04-25 CA CA002371635A patent/CA2371635A1/en not_active Abandoned
- 2000-04-25 BR BR0010070-6A patent/BR0010070A/pt not_active IP Right Cessation
- 2000-04-25 NZ NZ514895A patent/NZ514895A/en unknown
- 2000-04-25 CN CN00806904A patent/CN1349405A/zh active Pending
- 2000-04-25 PL PL00351678A patent/PL351678A1/xx not_active Application Discontinuation
- 2000-04-25 WO PCT/EP2000/003747 patent/WO2000066129A2/en not_active Application Discontinuation
- 2000-04-25 KR KR1020017013699A patent/KR20010110807A/ko not_active Application Discontinuation
- 2000-04-25 IL IL14594000A patent/IL145940A0/xx unknown
- 2000-04-25 HU HU0201875A patent/HUP0201875A3/hu unknown
- 2000-04-25 TR TR2001/03116T patent/TR200103116T2/xx unknown
- 2000-04-25 CZ CZ20013874A patent/CZ20013874A3/cs unknown
- 2000-04-25 MX MXPA01010976A patent/MXPA01010976A/es unknown
- 2000-04-25 RU RU2001131730/14A patent/RU2234321C2/ru not_active IP Right Cessation
- 2000-04-25 EP EP00920742A patent/EP1178807B1/en not_active Expired - Lifetime
-
2001
- 2001-10-23 ZA ZA200108741A patent/ZA200108741B/xx unknown
- 2001-10-25 NO NO20015207A patent/NO20015207L/no not_active Application Discontinuation
-
2002
- 2002-05-22 HK HK02103844.0A patent/HK1041834A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL145940A0 (en) | 2002-07-25 |
| NO20015207D0 (no) | 2001-10-25 |
| ZA200108741B (en) | 2003-07-23 |
| MXPA01010976A (es) | 2002-07-22 |
| EP1178807A2 (en) | 2002-02-13 |
| TR200103116T2 (tr) | 2002-04-22 |
| NZ514895A (en) | 2004-06-25 |
| NO20015207L (no) | 2001-10-25 |
| PL351678A1 (en) | 2003-06-02 |
| JP2002543136A (ja) | 2002-12-17 |
| HUP0201875A2 (en) | 2002-10-28 |
| EP1178807B1 (en) | 2004-09-29 |
| CN1349405A (zh) | 2002-05-15 |
| WO2000066129A3 (en) | 2001-04-19 |
| CZ20013874A3 (cs) | 2002-06-12 |
| AU771059B2 (en) | 2004-03-11 |
| HK1041834A1 (zh) | 2002-07-26 |
| RU2234321C2 (ru) | 2004-08-20 |
| KR20010110807A (ko) | 2001-12-13 |
| WO2000066129A2 (en) | 2000-11-09 |
| CA2371635A1 (en) | 2000-11-09 |
| BR0010070A (pt) | 2002-01-15 |
| AU4120400A (en) | 2000-11-17 |
| ATE277618T1 (de) | 2004-10-15 |
| DE60014358D1 (de) | 2004-11-04 |
| HUP0201875A3 (en) | 2003-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2189819C2 (ru) | Схемы приема прогестогена-антипрогестогена | |
| US20110059928A1 (en) | Graduated estrogen contraceptive | |
| US20070004690A1 (en) | Quadraphasis continuous graduated estrogen contraceptive | |
| US6506390B2 (en) | Progestogen-anti-progestogen regimens | |
| KR20060126671A (ko) | 에스트로겐 및 프로게스틴을 포함하는 연장 사용 조합제 | |
| SK284538B6 (sk) | Progesterónantagonisticky a antiestrogénne účinné zlúčeniny na spoločné použitie na výrobu ženskej antikoncepcie | |
| JPH10513152A (ja) | 抗黄体ホルモンおよびプロゲスチンを含有する周期相ホルモン養生法 | |
| SK285056B6 (sk) | Použitie estroprogestatívnej hormonálnej kompozície | |
| US6642219B1 (en) | Progestogen-antiprogestogen regimens | |
| JPS62205024A (ja) | エストロゲン欠乏症治療用組成物 | |
| JP2003511399A (ja) | 女性避妊薬の成分としてのメソプロゲスチン（プロゲステロン受容体モジュレーター） | |
| CA2248841C (en) | Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy | |
| SK15502001A3 (sk) | Použitie Org 33245 | |
| AU2003206424B2 (en) | Sequential estrogen/progesterone antagonist combination for hormone replacement therapy | |
| CZ20001753A3 (cs) | Balení pro antikoncepční účely | |
| MXPA00004610A (es) | Regimenes de progestogeno-anti-progestogeno | |
| MXPA01008772A (es) | Uso de hormonas sexuales para obtener una composicion farmaceutica nasal que es util en el tratamiento del sangrado uterino indeseable | |
| MXPA98010747A (es) | Regimenes de progestogeno-anti-progestogeno |